Barclays analyst Peter Lawson raised the firm’s price target on Biomea Fusion (BMEA) to $11 from $9 and keeps an Equal Weight rating on the shares post the Q3 report. Biomea on track to provide Phase 2 data in both type 1 and type 2 diabetes in December, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Biomea Fusion reports Q3 EPS (91c), consensus (95c)
- Biomea Fusion options imply 6.1% move in share price post-earnings
- Biomea Fusion Inc (BMEA) Q3 Earnings Cheat Sheet
- Biomea Fusion announces approval of ‘icovamenib’ as INN for BMF-219
- Morning Movers: Arcadium Lithium surges after deal to be acquired